Page 22 - T-I JOURNAL19 4

670 PARK

2018 Apr 11]. https://nyti.ms/2qnOvGv. ms/2v3X5PN.
42. CBS News. Should firms be able to own 54. Cook-Deegan R, Niehaus A. After Myr-
your genes? 1 Apr 2010 [accessed 2018 iad: genetic testing in the wake of recent
Apr 11]. https://www.cbsnews.com/news/ Supreme Court decisions about gene patents.
should-firms-be-able-to-own-your-genes/. Current Genetic Medical Report. 2014 Sep
43. Burk D. Feminism and dualism in intellectual 11;2(4):223-241.
property. Am Univ J Gender Soc Policy Law. 55. BRCA1- and BRCA2-Based Hereditary Cancer
2007;15(2):183. Test Patent Litigation, BF.Supp. 3d 1213, (D. Utah
44. Diamond v. Chakrabarty, 447 U.S. 303 (1980). 2014).
45. Laboratory Corp. of America Holdings v. Metab- 56. BRCA1- & BRCA2-Based Hereditary Cancer
olite Labs, 548 U.S. 124 (2006). Test Patent Litig., 774 F.3d 755 (Fed. Cir. 2014).
46. Myriad Defendants, Memo of Law (1) In Support 57. In re Roslin Inst. (Edinburgh), 750 F.3d 1333
of Their Motion for Summary Judgement and (Fed. Cir. 2014).
(2) In Opp. to Plaintiffs’ Motion for Summary 58. Genetic Techs. Ltd. v. Merial L.L.C., 818 F.3d
Judgement, Ass’n for Molecular Pathology, 702 1369, 1378 (Fed. Cir. 2016).
F. Supp. 2d 181 (S.D.N.Y. filed 2009). 59. Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788
47. Rai A. Engaging facts and policy: a multi-in- F.3d 1371, 1379 (Fed. Cir. 2015).
stitutional approach to patent system reform. 60. A Genetic Alliance Project. Free the Data.
Columb Law Rev. 2003;103(5):1035. [accessed 2018 Apr 11]. http://www.free-the-
48. Biotechnology Industry Organization. Gene data.org.
patent myths. 2012 May 24.
49. Memo. of Law (1) in Further Support of Pls.’ 61. Mandavilli A. A new high-tech, grass-roots
effort to fight breast cancer. Slate. 2013 Jun
Motion for Summary Judgment Against All 25. [accessed 2018 Apr 11]. http://www.
Defs. and (2) in Opposition to the Myriad Defs.’ slate.com/blogs/future_tense/2013/ 06/25/
Motion for Summary Judgment and (3) in Opp. free_ the_data_project_seeks_to_collect_myr-
to Def. United States. Patent and Trademark iad_reports_on_breast_cancer_genes.html.
Office’s Motion for Judgment on the Pleadings,
Ass’n for Molecular Pathology, 702 F. Supp. 2d 62. Br. Amici Curiae of ACLU et al. in Supp. of Defs.’
181 (S.D.N.Y. Jan. 20, 2010). Opp’n to Pls.’ Mot. Prelim. Inj., In re BRCA1-,
50. Begley S. As revenue falls, a pioneer of cancer BRCA2-Based Hereditary Cancer Test Patent
gene testing slams rivals with overblown claims. Litig., No. 2:13-CV-00640-RJS (D. Utah Mar.
STAT News. 2016 Nov 29 [accessed 2018 Apr 102014).
11]. https://www.statnews.com/ 2016/11/29/ 63. Br. Amici Curiae of ACLU et al., in re BRCA1- &
brca-cancer-myriad-genetic-tests/. BRCA2-Based Hereditary Cancer Test Patent
51. Matloff ET, Barnett ER, Nussbaum R. Choosing Litig., 774 F.3d 755, 2014 WL 2813346 (Fed. Cir.
a BRCA genetic testing laboratory: a patient-cen- 2014).
tric and ethical call to action for clinicians 64. Supplemental Br. Amici Curiae of ACLU et al.,
and payers. Am J of Manag Care. 2014 May In re BRCA1- & BRCA2-Based Hereditary Can-
15 [accessed 2018 Apr 11]. http://www.ajmc. cer Test Patent Litig., 774 F.3d 755, 2014 WL
com/journals/evidence-based-oncology/2014/ 5106262 (Fed. Cir. 2014).
may-2014/choosing-a-brca-genetic-testing-lab- 65. Murphy L, Park S. Comments to the U.S. Patent
oratory-a-patient-centric-and-ethical-call-to- & Trademark Office Re: Guidance for Deter-
action-for-clinicians-and-payers. mining Subject Matter Eligibility of Claims
52. Decl. of Roger Klein, Ass’n for Molecular Pathol- Reciting or Involving Laws of Nature, Natu-
ogy, 702 F. Supp. 2d 181 (S.D.N.Y. Jan. 20, 2010) ral Phenomena, & Natural Products. 2014 Jul
53. Pollack A. After DNA patent ruling, availabil- 8 [accessed 2018 Apr 11]. https://www.uspto.
ity of genetic tests could broaden. NY Times. gov/sites/default/files/patents/law/comments/
2013 Jun 14 [accessed 2018 Apr 11]. https://nyti. mm-f-aclu20140710.pdf.